Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AKRO

AKRO - Akero Therapeutics Inc Stock Price, Fair Value and News

26.99USD-0.24 (-0.88%)Market Closed
Watchlist

Market Summary

USD26.99-0.24
Market Closed
-0.88%

AKRO Alerts

  • JANUS HENDERSON GROUP PLC reported owning 7.7% of AKRO [2024-02-13]

AKRO Stock Price

View Fullscreen

AKRO RSI Chart

AKRO Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-10.01

Price/Free Cashflow

-10.45

AKRO Price/Sales (Trailing)

AKRO Profitability

Return on Equity

-28.35%

Return on Assets

-26.15%

Free Cashflow Yield

-9.57%

AKRO Fundamentals

AKRO Earnings

Earnings (TTM)

-151.8M

Earnings Growth (Yr)

-139.33%

Earnings Growth (Qtr)

-39.15%

Breaking Down AKRO Revenue

Last 7 days

5.7%

Last 30 days

-6.9%

Last 90 days

33.7%

Trailing 12 Months

-52.8%

How does AKRO drawdown profile look like?

AKRO Financial Health

Current Ratio

29.27

AKRO Investor Care

Shares Dilution (1Y)

19.86%

Diluted EPS (TTM)

-2.89

Tracking the Latest Insider Buys and Sells of Akero Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 02, 2024
cheng andrew
acquired
24,600
0.615
40,000
president and ceo
Dec 27, 2023
young jonathan
acquired
34,433
6.36
5,414
chief operating officer
Dec 27, 2023
young jonathan
sold
-129,936
24.00
-5,414
chief operating officer
Dec 14, 2023
cheng andrew
sold
-33,797
20.76
-1,628
president and ceo
Dec 14, 2023
young jonathan
sold
-11,272
20.76
-543
chief operating officer
Dec 14, 2023
white william richard
sold
-12,684
20.76
-611
chief financial officer
Dec 14, 2023
rolph timothy
sold
-10,670
20.76
-514
chief scientific officer
Dec 14, 2023
yale catriona
sold
-12,393
20.76
-597
chief development officer
Dec 11, 2023
cheng andrew
acquired
47,095
6.36
7,405
president and ceo
Dec 11, 2023
cheng andrew
sold
-148,273
20.0233
-7,405
president and ceo

1–10 of 50

Which funds bought or sold AKRO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
-699,956
595,752
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
new
-
512,000
512,000
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
reduced
-40.24
-59,313,000
22,597,500
0.50%
Feb 23, 2024
Chicago Partners Investment Group LLC
unchanged
-
246,708
551,124
0.03%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
sold off
-100
-25,991,800
-
-%
Feb 20, 2024
Able Wealth Management LLC
new
-
794
794
-%
Feb 20, 2024
Quarry LP
added
40.00
-22,362
40,863
0.01%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-3.52
-106,887,000
85,834,000
0.01%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-1,042,000
-
-%
Feb 16, 2024
Clarity Asset Management, Inc.
new
-
981
981
-%

1–10 of 39

Are Funds Buying or Selling AKRO?

Are funds buying AKRO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AKRO
No. of Funds

Unveiling Akero Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
price t rowe associates inc /md/
6.6%
3,681,209
SC 13G
Feb 14, 2024
pfizer inc
4.53%
2,525,252
SC 13G/A
Feb 14, 2024
rtw investments, lp
6.4%
3,592,759
SC 13G
Feb 14, 2024
redmile group, llc
2.0%
1,109,476
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
4.3%
2,368,378
SC 13G/A
Feb 13, 2024
avidity partners management lp
0.4%
235,000
SC 13G/A
Feb 13, 2024
janus henderson group plc
7.7%
4,306,401
SC 13G/A
Feb 13, 2024
alkeon capital management llc
6.8%
3,764,220
SC 13G/A
Feb 13, 2024
vanguard group inc
5.54%
3,085,048
SC 13G
Feb 08, 2024
wellington management group llp
5.17%
2,881,989
SC 13G

Recent SEC filings of Akero Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 29, 2024
10-K
Annual Report
Feb 29, 2024
8-K
Current Report
Feb 29, 2024
S-8
Employee Benefits Plan
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Akero Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
35.3B
6.8B
-16.59% -47.80%
-7.48
5.15
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.0B
1.8B
-23.99% -31.71%
-43.22
10.41
76.23% 61.08%
16.3B
2.4B
-4.89% -18.90%
97.14
6.73
15.42% 18.43%
13.1B
3.7B
-7.62% -26.87%
21.93
3.55
8.87% 75.42%
MID-CAP
7.5B
396.6M
-2.06% 34.31%
-14.13
18.83
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.64
60.35
54.84% -25.61%
4.0B
240.7M
-19.08% -10.99%
-13.4
16.52
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.11
14.24
440.80% -27.84%
3.8B
726.4M
-12.60% 32.37%
-62.46
5.27
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-3.38% -9.50%
26.46
4.74
85.90% -14.05%
687.2M
983.7M
-9.17% -57.89%
-1.26
0.7
-50.36% 17.16%
201.6M
4.9M
-14.18% -58.18%
-1.22
41.23
-57.57% 50.48%
135.5M
881.7K
289.54% 381.25%
-2.86
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Akero Therapeutics Inc News

Latest updates
InvestorsObserver12 hours ago
The Motley Fool4 months ago

Akero Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-8.7%58063566434935737918617019622423825827330011412713815016312077.00
  Current Assets-2.8%560576643347355378184168194222236256271298113126138150163-77.00
    Cash Equivalents-13.1%23427044425825037417815115116515818818719363.0047.0065.0014816370.0076.00
  Net PPE-10.0%0.000.000.000.000.000.000.000.000.000.000.000.000.000.00-------
Liabilities-13.9%45.0052.0047.0042.0030.0036.0037.0023.0026.0025.0018.0012.0015.0014.0010.008.009.007.005.004.002.00
  Current Liabilities-32.8%19.0028.0022.0017.0019.0025.0027.0022.0025.0024.0016.0010.0013.0012.0010.008.009.007.005.00-2.00
Shareholder's Equity-8.2%53558361630632734414814716919922024625928610411812914315837.0037.00
  Retained Earnings-10.6%-574-518-479-448-422-399-363-336-310-277-253-224-209-179-158-142-130-114-99.15--86.56
  Additional Paid-In Capital0.6%1,1091,1031,096754749743512483479477474471468466262260259258258-37.00
Shares Outstanding0.1%56.0056.0056.0047.0047.0036.0035.0035.0035.0035.0035.0035.00---------
Float-------340,435---768---478---196--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations2.2%-48,627-49,719-22,389-24,632-25,508-24,624-19,509-22,876-26,695-14,606-20,034-18,346-23,395-13,508-22,584-11,317-11,649-13,212-5,322-5,444-
  Share Based Compensation6.6%6,1165,7394,7984,8444,04011,7314,1613,3112,6422,6122,4362,3641,9161,5461,3231,237670483402215-
Cashflow From Investing110.2%12,786-125,697-128,30217,590-101,4453,00011,87022,75012,00021,934-10,65419,00017,899-59,84438,465-6,281-----
Cashflow From Financing-37.7%502806336,85515,1532,723217,90034,87713224369.0026624.0059.00202,784100164115-1,60798,200-720-

AKRO Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 38,634$ 25,087$ 88,406$ 66,964
General and administrative7,98111,00422,59122,772
Total operating expenses46,61536,091110,99789,736
Loss from operations(46,615)(36,091)(110,997)(89,736)
Interest expense(888)(324)(2,202)(377)
Other income, net7,84487316,6261,139
Net loss(39,659)(35,542)(96,573)(88,974)
Net unrealized (loss) gain on marketable securities(255)3(543)27
Comprehensive loss$ (39,914)$ (35,539)$ (97,116)$ (88,947)
Net loss per share, basic$ (0.71)$ (0.92)$ (1.87)$ (2.45)
Net loss per share, diluted$ (0.71)$ (0.92)$ (1.87)$ (2.45)
Weighted-average number of shares used in computing net loss per common share, basic55,613,12038,663,46951,506,76636,364,284
Weighted-average number of shares used in computing net loss per common share, diluted55,613,12038,663,46951,506,76636,364,284

AKRO Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 269,546$ 249,773
Short-term marketable securities285,186101,676
Prepaid expenses and other current assets21,2473,724
Total current assets575,979355,173
Long-term marketable securities58,264 
Property and equipment, net2047
Right of use asset1,0681,242
Other assets, noncurrent 108
Total assets635,331356,570
Current liabilities:  
Accounts payable11,4547,968
Accrued expenses and other current liabilities14,91711,115
Loan Payable - current2,076 
Total current liabilities28,44719,083
Loan payable, noncurrent22,7689,541
Warrant liability93305
Operating lease liability, noncurrent8881,079
Total liabilities52,19630,008
Commitments and contingencies (Note 12)
Stockholders' equity:  
Common stock, $0.0001 par value, 150,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 55,681,026 and 46,865,206 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively65
Additional paid-in capital1,102,545748,857
Accumulated other comprehensive (loss) income(506)37
Accumulated deficit(518,910)(422,337)
Total stockholders' equity583,135326,562
Total liabilities and stockholders' equity$ 635,331$ 356,570
AKRO
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.akerotx.com
 EMPLOYEES44

Akero Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Akero Therapeutics Inc? What does AKRO stand for in stocks?

AKRO is the stock ticker symbol of Akero Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akero Therapeutics Inc (AKRO)?

As of Thu Feb 29 2024, market cap of Akero Therapeutics Inc is 1.5 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKRO stock?

You can check AKRO's fair value in chart for subscribers.

What is the fair value of AKRO stock?

You can check AKRO's fair value in chart for subscribers. The fair value of Akero Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Akero Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AKRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Akero Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AKRO is over valued or under valued. Whether Akero Therapeutics Inc is cheap or expensive depends on the assumptions which impact Akero Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKRO.